164 related articles for article (PubMed ID: 15454688)
1. In vitro models in endocrine disruptor screening.
Charles GD
ILAR J; 2004; 45(4):494-501. PubMed ID: 15454688
[TBL] [Abstract][Full Text] [Related]
2. Uncertainties for endocrine disrupters: our view on progress.
Daston GP; Cook JC; Kavlock RJ
Toxicol Sci; 2003 Aug; 74(2):245-52. PubMed ID: 12730617
[TBL] [Abstract][Full Text] [Related]
3. Use of the laboratory rat as a model in endocrine disruptor screening and testing.
Gray LE; Wilson V; Noriega N; Lambright C; Furr J; Stoker TE; Laws SC; Goldman J; Cooper RL; Foster PM
ILAR J; 2004; 45(4):425-37. PubMed ID: 15454681
[TBL] [Abstract][Full Text] [Related]
4. Selecting appropriate animal models and experimental designs for endocrine disruptor research and testing studies.
Stokes WS
ILAR J; 2004; 45(4):387-93. PubMed ID: 15454677
[TBL] [Abstract][Full Text] [Related]
5. Commentary: setting aside tradition when dealing with endocrine disruptors.
Colborn T
ILAR J; 2004; 45(4):394-400. PubMed ID: 15454678
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Tier I screening approaches for detecting endocrine-active compounds (EACs).
O'Connor JC; Cook JC; Marty MS; Davis LG; Kaplan AM; Carney EW
Crit Rev Toxicol; 2002; 32(6):521-49. PubMed ID: 12487364
[TBL] [Abstract][Full Text] [Related]
7. Factors considered in using birds for evaluating endocrine-disrupting chemicals.
Touart LW
ILAR J; 2004; 45(4):462-8. PubMed ID: 15454685
[TBL] [Abstract][Full Text] [Related]
8. Answering the endocrine test questions.
Schmidt CW
Environ Health Perspect; 1999 Sep; 107(9):A458-60. PubMed ID: 10464085
[TBL] [Abstract][Full Text] [Related]
9. Use and role of invertebrate models in endocrine disruptor research and testing.
deFur PL
ILAR J; 2004; 45(4):484-93. PubMed ID: 15454687
[TBL] [Abstract][Full Text] [Related]
10. Key learnings from performance of the U.S. EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 in vitro assays.
LeBaron MJ; Coady KK; O'Connor JC; Nabb DL; Markell LK; Snajdr S; Sue Marty M
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):23-42. PubMed ID: 24515815
[TBL] [Abstract][Full Text] [Related]
11. Approaches to the assessment of toxicity data with endpoints related to endocrine disruption.
Harvey PW; Johnson I
J Appl Toxicol; 2002; 22(4):241-7. PubMed ID: 12210541
[TBL] [Abstract][Full Text] [Related]
12. Selecting the appropriate rodent diet for endocrine disruptor research and testing studies.
Thigpen JE; Setchell KD; Saunders HE; Haseman JK; Grant MG; Forsythe DB
ILAR J; 2004; 45(4):401-16. PubMed ID: 15454679
[TBL] [Abstract][Full Text] [Related]
13. Lessons learned, challenges, and opportunities: the U.S. Endocrine Disruptor Screening Program.
Juberg DR; Borghoff SJ; Becker RA; Casey W; Hartung T; Holsapple MP; Marty MS; Mihaich EM; Van Der Kraak G; Wade MG; Willett CE; Andersen ME; Borgert CJ; Coady KK; Dourson ML; Fowle JR; Gray LE; Lamb JC; Ortego LS; Schug TT; Toole CM; Zorrilla LM; Kroner OL; Patterson J; Rinckel LA; Jones BR
ALTEX; 2014; 31(1):63-78. PubMed ID: 24114257
[TBL] [Abstract][Full Text] [Related]
14. Endocrine disrupters--testing strategies to assess human hazard.
Baker VA
Toxicol In Vitro; 2001; 15(4-5):413-9. PubMed ID: 11566572
[TBL] [Abstract][Full Text] [Related]
15. Application of an integrated testing strategy to the U.S. EPA endocrine disruptor screening program.
Willett CE; Bishop PL; Sullivan KM
Toxicol Sci; 2011 Sep; 123(1):15-25. PubMed ID: 21642633
[TBL] [Abstract][Full Text] [Related]
16. Failure to Launch: The Endocrine Disruptor Screening Program at the U.S. Environmental Protection Agency.
Maffini MV; Vandenberg LN
Front Toxicol; 2022; 4():908439. PubMed ID: 35707496
[TBL] [Abstract][Full Text] [Related]
17. Endocrine-disrupting chemicals: prepubertal exposures and effects on sexual maturation and thyroid function in the male rat. A focus on the EDSTAC recommendations. Endocrine Disrupter Screening and Testing Advisory Committee.
Stoker TE; Parks LG; Gray LE; Cooper RL
Crit Rev Toxicol; 2000 Mar; 30(2):197-252. PubMed ID: 10759431
[TBL] [Abstract][Full Text] [Related]
18. The use and acceptance of Other Scientifically Relevant Information (OSRI) in the U.S. Environmental Protection Agency (EPA) Endocrine Disruptor Screening Program.
Bishop PL; Willett CE
Birth Defects Res B Dev Reprod Toxicol; 2014 Feb; 101(1):3-22. PubMed ID: 24151143
[TBL] [Abstract][Full Text] [Related]
19. Xenoendocrine disrupters-tiered screening and testing: filling key data gaps.
Gray LE; Ostby J; Wilson V; Lambright C; Bobseine K; Hartig P; Hotchkiss A; Wolf C; Furr J; Price M; Parks L; Cooper RL; Stoker TE; Laws SC; Degitz SJ; Jensen KM; Kahl MD; Korte JJ; Makynen EA; Tietge JE; Ankley GT
Toxicology; 2002 Dec; 181-182():371-82. PubMed ID: 12505339
[TBL] [Abstract][Full Text] [Related]
20. Tiered screening and testing strategy for xenoestrogens and antiandrogens.
Gray LE
Toxicol Lett; 1998 Dec; 102-103():677-80. PubMed ID: 10022334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
